SecBot SecBot
8-K ·Filed Nov 12, 2026

PMN

ProMIS Neurosciences Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed4d 19h ago SEC0001104659-26-125896
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

The 12-month PRECISE-AD topline data in Q1 2027 is the next major catalyst. The interim safety and biomarker signals are favorable but blinded; unblinded efficacy data will determine the stock's direction.

DirectionNeutral
Confidencehigh
Horizonmonths

Drug in focus

PMN drug pipeline →

PMN310

▲ Bullish Named in this 8-K
Impact
Phase
Phase 1b
Time to market
Years away — Phase 1b enrollment complete, but Phase 2/3 trials, if initiated, would take multiple years. Best-case earliest approval likely 2029+.
Next catalyst
None dated

What to watchThe Phase 1b PRECISE-AD interim analysis (blinded 6-month biomarker data) is the critical near-term catalyst, expected within weeks. Positive biomarker signals (Aβ oligomer reduction, pTau) could send the stock sharply higher given the low float and ~$12.80 share price vs. ~$32 mean analyst target. However, a Phase 1b readout is not de-risking enough to guarantee Phase 2/3 success, and the competitive Alzheimer's landscape is crowded with approved drugs (lecanemab, donanemab).

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$3.48
T+0 close · Nov 12, 2026 · via day close
Latest settled
−5.46%
T+1 · $3.29
Vs SPY
−5.10%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $3.48entry
  2. T+1 · 4d ago −5.46%α −5.10% · $3.29
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ProMIS Neurosciences filed an 8-K with an updated corporate presentation summarizing its PRECISE-AD Phase 1b interim data for PMN310 in early Alzheimer's disease. The presentation highlights zero ARIA-E, 4.4% total ARIA (all mild ARIA-H), and declining biomarker signals (plasma pTau217 -15%, CSF MTBR-tau243 -13.3%) at the 6-month blinded interim, with 12-month topline data expected in Q1 2027.

Key Facts

  • PRECISE-AD Phase 1b 6-month blinded interim: 0.0% ARIA-E, 4.4% total ARIA (all mild ARIA-H), no treatment-related SAEs or discontinuations.
  • Plasma pTau217 declined 15% from baseline at Day 169; 68.5% of patients declined.
  • CSF MTBR-tau243 declined 13.3% from baseline at Day 169; 62.5% of patients declined.
  • 144 patients enrolled across 22 sites; 136 safety-evaluable; 61% APOE4 carriers, 11% homozygotes.
  • 12-month topline data expected in Q1 2027; cash runway through 2027.
  • PMN310 has FDA Fast Track designation.

Financial Impact

No financial data in filing; market cap $36M. Filing is an investor presentation update with no revenue or financial results.

Risk Factors

  • Blinded interim data may not predict unblinded 12-month results; Phase 1b is not powered for statistical significance on clinical endpoints.
  • Early-stage clinical data may not replicate in larger registrational trials.
  • Cash runway through 2027 depends on no unforeseen capital needs.
  • Cross-trial comparisons with approved anti-amyloid therapies are illustrative, not head-to-head.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-125896
Document: pmn-20261111x8k.htm0001104659-26-125896
Document: 0001104659-26-125896-index-headers.html0001104659-26-125896
Document: 0001104659-26-125896-index.html0001104659-26-125896
Document: 0001104659-26-125896.txt0001104659-26-125896

Track record

16 reports on PMN

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +43.16% at T+60 after the Mar 18, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 17, 2026today Press Release Neutral 3/10 Entry $3.28 Now $3.31 +0.91% settles Nov 18
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $3.25 Now $3.31 +1.85% settles Nov 18
  3. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $3.29 to $3.31 Now $3.31 +0.61% ▲ +0.61% +2.52% vs SPY
  4. Nov 12, 20264d ago SC 13G Neutral 4/10 Entry $3.48 to $3.29 Now $3.31 −4.89% ▼ −5.46% −5.10% vs SPY
  5. Nov 12, 20264d ago 8-K Neutral 5/10 Viewing Entry $3.48 to $3.29 Now $3.31 −4.89% ▼ −5.46% −5.10% vs SPY
  6. Nov 6, 202610d ago Insider Cluster Bullish 4/10 Entry $4.16 to $4.05 Now $3.31 −20.43% ▼ −2.64% −5.01% vs SPY
  7. Nov 5, 202611d ago Press Release Neutral 2/10 Entry $3.65 to $4.16 Now $3.31 −9.32% ▲ +13.97% +13.66% vs SPY
  8. Oct 6, 20265w ago 3 Neutral 2/10 Entry $9.12 to $9.15 Now $3.31 −63.71% ▲ +0.33% +0.75% vs SPY
  9. Oct 6, 20265w ago Press Release Neutral 3/10 Entry $9.21 to $9.12 Now $3.31 −64.06% ▼ −0.98% −0.74% vs SPY
  10. Sep 1, 202610w ago Press Release Neutral 3/10 Entry $13.35 to $13.98 Now $3.31 −75.21% ▲ +4.68% +4.24% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 9m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026